Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia GS-US-312-0123

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Gilead Sciences, Inc.

Start Date

August 11, 2014

End Date

October 11, 2017
 

Administered By

Duke Cancer Institute

Awarded By

Gilead Sciences, Inc.

Start Date

August 11, 2014

End Date

October 11, 2017